Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

BRK Extends its Footprint into Europe and CIS and "EV" Vehicles with Key Appointment

PR Newswire September 9, 2020

Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA

PR Newswire September 9, 2020

LD Micro - 360 Companies - Set to Present this Week

Accesswire August 31, 2020

Moleculin to Present at LD Micro 500 Virtual Investor Conference

PR Newswire August 27, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020

PR Newswire August 12, 2020

Additional Independent Research Further Supports Glucose Metabolism as Important COVID-19 Target

PR Newswire July 29, 2020

Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

PR Newswire July 21, 2020

Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate

PR Newswire July 15, 2020

Moleculin Provides Update on Annamycin Clinical Development

PR Newswire July 2, 2020

New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model

PR Newswire July 1, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Moleculin Biotech, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA June 30, 2020

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

GlobeNewswire June 29, 2020

Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

PR Newswire June 25, 2020

Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020

GlobeNewswire June 23, 2020

Moleculin to Present at the Life Sciences Investor Forum

PR Newswire June 23, 2020

Moleculin Announces Confirmatory In Vitro Analysis of WP1122

PR Newswire June 16, 2020

Moleculin Announces Submission to Expand Clinical Sites in European AML Trial

PR Newswire June 4, 2020

Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment

PR Newswire June 2, 2020

Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

PR Newswire May 27, 2020

Nasdaq Scheduled Resumption in Moleculin Biotech, Inc.

GlobeNewswire May 27, 2020